(Q43253466)

17 November 2017

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes (English)

1 reference

chronic obstructive pulmonary disease

17 November 2017

1 reference

1 reference

Glenn Crater

10

0 references

Antonio Anzueto

1

object named as

Antonio Anzueto

1 reference

17 November 2017

Gary T Ferguson

2

1 reference

17 November 2017

Greg Feldman

3

1 reference

17 November 2017

Kenneth Chinsky

4

1 reference

17 November 2017

Allan Seibert

5

1 reference

17 November 2017

Amanda Emmett

6

1 reference

17 November 2017

Katharine Knobil

7

1 reference

17 November 2017

Dianne O'Dell

8

1 reference

17 November 2017

Christopher Kalberg

9

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

17 November 2017

1 reference

17 November 2017

6

1 reference

17 November 2017

320-329

1 reference

17 November 2017

5

1 reference

Burden and clinical features of chronic obstructive pulmonary disease (COPD).

17 November 2017

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550903140881

10.1080/15412550903140881

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference